HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis

Oncology Reports

Volumn 23, Issue 4, 2010, Pages 933-939

  Bandoh, Nobuyuki ^a,b   Ogino, Takeshi ^a   Katayama, Akihiro ^a   Takahara, Miki ^a   Katada, Akihiro ^a   Hayashi, Tatsuya ^a   Harabuchi, Yasuaki ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b Hokuto Hospital   (Japan)

Author keywords

Head and neck squamous cell carcinoma; HLA class I antigen; Tapasin; Transporter associated with antigen processing

Indexed keywords

HLA ANTIGEN CLASS 1; PARAFFIN; PEROXIDASE; TAPASIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STAINING;

AGED; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEAD AND NECK NEOPLASMS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 77949448480     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000717     Document Type: Article

References (35)

1. Marincola FM, Jaffee EM, Hicklin DJ and Ferrone S: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74: 181-273, 2000.
2. Seliger B, Cabrera T, Garrido F and Ferrone S: HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12: 3-13, 2002.
3. Chang CC, Campoli M and Ferrone S: HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? Curr Opin Immunol 16: 644-650, 2004.
4. Ferrone S and Whiteside TL: Tumor microenvironment and immune escape. Surg Oncol Clin N Am 16: 755-774, viii, 2007.
5. Ferrone S: Immunotherapy dispenses with tumor antigens. Nat Biotechnol 22: 1096-1098, 2004.
6. Lehner PJ, Surman MJ and Cresswell P: Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line .220. Immunity 8: 221-231, 1998.
7. Fruh K, Gossen M, Wang K, Bujard H, Peterson PA and Yang Y: Displacement of housekeeping proteasome subunits by MHC-encoded LMPs: a newly discovered mechanism for modulating the multicatalytic proteinase complex. EMBO J 13: 3236-3244, 1994.
8. Pamer E and Cresswell P: Mechanisms of MHC class I - restricted antigen processing. Annu Rev Immunol 16: 323-358, 1998.
9. Cresswell P, Arunachalam B, Bangia N, et al: Thiol oxidation and reduction in MHC-restricted antigen processing and presentation. Immunol Res 19: 191-200, 1999.
10. Zinkernagel RM and Doherty PC: MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restrictionspecificity, function, and responsiveness. Adv Immunol 27: 151-177, 1979.
11. Salter RD, Howell DN and Cresswell P: Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21: 235-246, 1985.
12. Garbi N, Tan P, Diehl AD, et al: Impaired immune responses and altered peptide repertoire in tapasin-deficient mice. Nat Immunol 1: 234-238, 2000.
13. Gao B, Adhikari R, Howarth M, et al: Assembly and antigenpresenting function of MHC class I molecules in cells lacking the ER chaperone calreticulin. Immunity 16: 99-109, 2002.
14. Esteban F, Concha A, Huelin C, et al: Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int J Cancer 43: 436-442, 1989.
15. Houck JR, Sexton FM and Zajdel G: HLA class I and class II antigen expression on squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 116: 1181-1185, 1990.
16. Mattijssen V, De Mulder PH, Schalkwijk L, Manni JJ, Van't Hof-Grootenboer B and Ruiter DJ: HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites. Int J Cancer (Suppl) 6: 95-100, 1991.
17. Vora AR, Rodgers S, Parker AJ, Start R, Rees RC and Murray AK: An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br J Cancer 76: 836-844, 1997.
18. Ogino T, Bandoh N, Hayashi T, et al: Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 9: 4043-4051, 2003.
19. Ferris RL, Hunt JL and Ferrone S: Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 33: 113-133, 2005.
20. Meissner M, Reichert TE, Kunkel M, et al: Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11: 2552-2560, 2005.
21. Ogino T, Shigyo H, Ishii H, et al: HLA class I antigen downregulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 66: 9281-9289, 2006.
22. Wang X, Campoli M, Cho HS, et al: A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods 299: 139-151, 2005.
23. Stam NJ, Spits H and Ploegh HL: Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137: 2299-2306, 1986.
24. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y and Ferrone S: Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 62: 385-393, 2003.
25. Kusama M, Kageshita T, Chen ZJ and Ferrone S: Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. J Immunol 143: 3844-3852, 1989.
26. Bandoh N, Ogino T, Cho HS, et al: Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 66: 185-194, 2005.
27. Charron D (ed). HLA and Cancer. EDK, Paris, pp445-452, 1997.
28. Feenstra M, Veltkamp M, van Kuik J, et al: HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens 54: 235-245, 1999.
29. Mehta AM, Jordanova ES, Kenter GG, Ferrone S and Fleuren GJ: Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57: 197-206, 2008.
30. Han LY, Fletcher MS, Urbauer DL, et al: HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 14: 3372-3379, 2008.
31. Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD and Morel PA: Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res 6: 2794-2802, 2000.
32. Cromme FV, van Bommel PF, Walboomers JM, et al: Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 69: 1176-1181, 1994.
33. Kaklamanis L, Leek R, Koukourakis M, Gatter KC and Harris AL: Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res 55: 5191-5194, 1995.
34. Atkins D, Ferrone S, Schmahl GE, Storkel S and Seliger B: Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol 171: 885-889, 2004.
35. Hosch SB, Izbicki JR, Pichlmeier U, et al: Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer 74: 582-587, 1997.